Replies to post #216481 on Biotech Values

[DewDiligence]

NKTR—Howard Robin (again) mentioned the possibility of 214 possibly being approved in Sarcoma on the one study given how poor outcomes are in that patient population. ...How plausible do you think that is?

That's highly plausible, IMO. For Stage-IV sarcoma, there are zero "targeted" drugs, PD-1 monotherapy hasn't worked well, and chemo is strictly palliative.